BCART.BR - Biocartis Group NV

Brussels - Brussels Delayed price. Currency in EUR

Biocartis Group NV

Generaal de Wittelaan 11 B
Mechelen 2800
32 1 563 26 00

IndustryDiagnostics & Research
Full-time employees526

Key executives

NameTitlePayExercisedYear born
Mr. Jean-Marc RoelandtChief Financial OfficerN/AN/A1965
Mr. Piet HouwenChief Operating OfficerN/AN/A1968
Mr. Roger MoodyChief Exec. OfficerN/AN/AN/A
Mr. Benoit DevogelaereChief Technology OfficerN/AN/A1981
Mr. Geert Maertens Ph.D.Chairman of Scientific Advisory Board & Chief Scientific OfficerN/AN/AN/A
Renate DegraveHead of IR & Corp. CommunicationsN/AN/AN/A
Ms. Susy SpruytHead of People & OrganizationN/AN/A1968
Dr. Erwin SablonHead of R&D and Alliance ManagementN/AN/A1965
Mr. Reginald Van GenechtenHead of Manufacturing & Supply ChainN/AN/A1966
Mr. Erik VossenaarVP of Bus. Devel.N/AN/A1973
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.

Corporate governance

Biocartis Group NV’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.